Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients (NEXT-REGIRI)

Clinical Trial ID NCT03829462

Rank	Title	Journal	Year	PubWeight™‹?›
1	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.	Lancet	2012	12.00
2	Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation.	Genes Dev	2000	3.72
3	An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene.	Cancer Res	2003	2.21
4	Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.	Br J Cancer	2014	0.90